Director, Value Demonstration & Access Evidence Strategy (Hematology)

pBeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer. /ph3Purpose of the Role /h3pShape evidence generation decisions during development to maximize future reimbursement, payer negotiations, HTA success and pricing potential. The Director, Value Demonstration Access Evidence Strategy is responsible for designing and implementing global payer and HTA evidence strategies that support successful reimbursement, access and pricing outcomes across the portfolio. The role serves as the strategic bridge between Clinical Development, HEOR, Medical Affairs, Regulatory Affairs and Global Value, Access Pricing (GVAP), ensuring that payer and HTA evidence requirements are incorporated into development programmes as early as possible. The individual will shape integrated evidence plans, anticipate evolving HTA and payer evidence expectations, and ensure that clinical, economic and real-world evidence generation activities support successful Joint Clinical Assessments (JCA), Joint Scientific Consultations (JSC), national HTA submissions, reimbursement negotiations, U.S. payer and value demonstration requirements, and lifecycle management strategies. The role is explicitly accountable for ensuring that U.S. evidence needs are surfaced early, reconciled against ex-U.S. HTA requirements, and reflected as a single, integrated set of requirements in development plans - rather than being raised late or handled separately. /ph3Key Responsibilities /h3h3Global Access Evidence Strategy /h3ulliDesign and implement global HTA and payer evidence strategies across the product lifecycle. /liliWork closely with GVAP Asset Leads, Regional Access Leads, country access leads and HEOR to identify the evidence requirements necessary to support Joint Scientific Consultations (JSC), Joint Clinical Assessments (JCA), national HTA assessments, reimbursement submissions and pricing negotiations. /liliEvaluate trade-offs between evidence options and recommend risk mitigation strategies that optimise payer, access, pricing and development objectives. /liliEnsure access evidence requirements are embedded within Integrated Evidence Plans. /li /ulh3Influence on Clinical Development /h3ulliIn close collaboration with GVAP Asset Leads and HEOR, provide expert market access and HTA input into clinical development programmes, registrational study design, comparator strategy, endpoint selection, patient population selection, subgroup evidence generation, PRO strategy and real-world evidence generation. /liliInfluence development decisions to proactively address future reimbursement risks rather than reacting to them post-approval. /li /ulh3U.S. Evidence Requirements Cross-Regional Reconciliation /h3ulliServe as the standing point of contact to the U.S. Value Access, U.S. HEOR and U.S. Medical teams for pipeline evidence planning. /liliSystematically elicit, document and prioritise U.S. payer, PBM, IDN and employer evidence requirements - including comparator expectations, endpoint and subgroup needs, real-world data requirements, AMCP-format dossier inputs and ICER assessment risk - and ensure these are represented in Integrated Evidence Plans alongside EU HTA and other ex-U.S. requirements. /liliIdentify and escalation conflicts between U.S. and ex-U.S. evidence requirements (e.g. divergent comparators, populations, or endpoint hierarchies) with a recommended resolution and an articulated trade-off, rather than deferring the decision. /liliAnticipate the access implications of U.S. policy developments, including CMS price negotiation and Medicare/Medicaid coverage dynamics, and translate these into evidence-generation requirements at the point where development decisions are still open. /li /ulh3Value Demonstration Evidence Generation /h3ulliDevelop and maintain asset-specific payer value demonstration plans. /liliShape, in tight collaboration with HEOR, evidence generation activities including cost-effectiveness analyses, budget impact models, RWE studies, PRO studies, long-term outcome analyses, indirect treatment comparisons and network meta-analyses. /liliCollaborate closely with HEOR and Medical Affairs teams to ensure evidence packages address stakeholder needs across global healthcare systems. /li /ulh3HTA Payer Landscape Monitoring /h3ulliMaintain deep expertise on evolving global HTA methodologies and payer evidence expectations, monitoring changes in the EU HTA Regulation, NICE, HAS, G-BA/IQWiG, AIFA, CADTH, ICER and other major payer and assessment bodies. Such monitoring covers U.S. payer, PBM and value-assessment developments on the same footing as EU and other ex-U.S. bodies, with implications translated into concrete evidence requirements for U.S.-relevant programmes. /liliTranslate emerging requirements into actionable evidence-generation strategies. /liliEnsure assets are prepared for both EU-level an /li /ul #J-18808-Ljbffr